NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Inovio
Pharmaceuticals (NYSEMKT: INO) plans to put its
HPV-related cancer and pre-cancer treatment, VGX-3100, through
Phase II trials in 2014.
Inovio Pharmaceuticals (INO) recently announced that its
revolutionary treatment, VGX-3100, is slated for a 2014 phase II
trial for its efficacy treating cervical dysplasia. The treatment
is just one of numerous products that Inovio has in the
pipeline.
In addition to VGX-3100, Inovio is prepping treatments and
vaccines for cervical, head and neck, prostate, breast, and lung
cancers. Further down the pipeline, the company is developing
revolutionary vaccines for HIV, hepatitis B, malaria, and hepatitis
C. Given the breadth and pervasiveness of the diseases the company
is targeting, Inovio estimates that its drugs could eventually be
used to treat billions of people.
Inovio's products are unique in the field of DNA vaccines, which
engineer the body's DNA platforms to achieve desired results.
Specifically, Inovio's active immunotherapy treatments target
t-cells for use against the body's diseased cells. Inovio then uses
a unique technological product called an electroporation device to
open pores in the targeted cells membrane. The treatment enters the
cells through those pores, creating a powerful immune system
resistant to the targeted disease.
The company has an experienced research leadership team, strong
ties to respected medical institutions, and a $400 million developmental partnership with
Roche, a worldwide leader in the development of drugs and
treatments for cancer. As Inovio's treatments come to market, the
company has a tremendous opportunity to save patients for
devastating diseases while also capitalizing on a massive
market.
For more information on Inovio Pharmaceuticals including a list
of the products in the pipeline, check out our free company report
here: http://bit.ly/INO-AnalystReport copy and paste may be
required
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Such forward-looking statements by definition involve risks,
uncertainties and other factors, which may cause the actual
results, performance or achievements of mentioned company to be
materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Marc Bonacci, Chief Analyst. An
outsourced research services provider represented by Marc Bonacci, Chief Analyst, has written and
reviewed the information in this article or report. BrokerBank
Securities, Inc. or Small Cap Street, LLC is not entitled to veto,
interfere or alter the articles, documents or report once created
and reviewed by the outsourced research provider represented by
Marc Bonacci, Chief Analyst. Small
Cap Street, LLC is the party responsible for hosting the full
analyst report on smallcapstreet.com. Marc Bonaccci, Chief Analyst,
is the author of research report. BrokerBank Securities, Inc. is
the party responsible for issuing this press release. Small Cap
Street has compensated Marc Bonacci
one hundred dollars for the right to
disseminate this press release and report. Information in this
release is fact checked and produced on a best efforts basis by
Marc Bonacci, Chief Analyst.
NOT FINANCIAL ADVICE
BrokerBank Securities, Inc. or Small Cap Street, LLC makes no
warranty, expressed or implied, as to the accuracy or completeness
or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to
be construed as personal financial advice. Readers are encouraged
to consult their personal financial advisor before making any
decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Companies mentioned have not compensated BrokerBank Securities,
Inc. Small Cap Street, LLC or Marc
Bonacci, Chief Analyst, for the creation or dissemination of
this press release. BrokerBank Securities, Inc. or Small Cap
Street, LLC. is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by BrokerBank
Securities, Inc. or Small Cap Street, LLC. whatsoever for any
direct, indirect or consequential loss arising from the use of this
document. BrokerBank Securities, Inc. or Small Cap Street, LLC.
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. BrokerBank Securities,
Inc. or Small Cap Street, LLC. does not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
BrokerBank Securities, Inc. is a member of the Financial
Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.